Biomarkers of abnormally invasive placenta.

Autor: Al-Khan A; Department of Obstetrics and Gynecology, Hackensack University Medical Center, Hackensack, NJ 07601, USA., Youssef YH; Department of Obstetrics and Gynecology, Hackensack University Medical Center, Hackensack, NJ 07601, USA., Feldman KM; Department of Obstetrics and Gynecology, Hackensack University Medical Center, Hackensack, NJ 07601, USA., Illsley NP; Department of Obstetrics and Gynecology, Hackensack University Medical Center, Hackensack, NJ 07601, USA. Electronic address: nicholas.illsley@hackensackmeridian.org., Remache Y; Department of Obstetrics and Gynecology, Hackensack University Medical Center, Hackensack, NJ 07601, USA., Alvarez-Perez J; Department of Obstetrics and Gynecology, Hackensack University Medical Center, Hackensack, NJ 07601, USA., Mannion C; Department of Pathology, Hackensack University Medical Center, Hackensack, NJ 07601, USA., Alvarez M; Department of Obstetrics and Gynecology, Hackensack University Medical Center, Hackensack, NJ 07601, USA., Zamudio S; Department of Obstetrics and Gynecology, Hackensack University Medical Center, Hackensack, NJ 07601, USA.
Jazyk: angličtina
Zdroj: Placenta [Placenta] 2020 Feb; Vol. 91, pp. 37-42. Date of Electronic Publication: 2020 Jan 23.
DOI: 10.1016/j.placenta.2020.01.007
Abstrakt: Introduction: Abnormally invasive placenta (AIP, aka placenta accreta spectrum; PAS) is an increasingly common pregnancy pathology, which, despite significant morbidity risk to the mother, is often undiagnosed prior to delivery. We tested several potential biomarkers in plasma from PAS mothers to determine whether any were sufficiently robust for a formal, diagnostic accuracy study.
Methods: We examined hyperglycosylated hCG (h-hCG), decorin and IL-8, based on biological plausibility and literature indications that they might be altered in PAS. These analytes were assayed by ELISA in maternal plasma from five groups, comprising (1) normal term controls, (2) placenta previa controls, and cases of (3) placenta increta/percreta without placenta previa, (4) placenta previa increta/percreta and (5) placenta previa accreta.
Results: There were no differences in h-hCG, ß-hCG or the h-hCG/ß-hCG ratio between the groups. Mean decorin levels were increased in previa controls (Group 2) compared to the other groups, but there was substantial overlap between the individual values. While an initial multiplex assay showed a greater value for IL-8 in the placenta previa increta/percreta group (Group 4) compared to placenta previa controls (Group 2), the subsequent validation ELISA for IL-8 showed no differences between the groups.
Discussion: We conclude that the absence of differences and the extent of overlap between cases and controls does not justify further assessment of these biomarkers.
(Copyright © 2020 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: